EPS Diluted (Annual) Chart

View EPS Diluted (Annual) for AZN.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View EPS Diluted (Annual) Chart
Start Trial

Historical EPS Diluted (Annual) Data

View and export this data back to 1990. Start Trial.
Date Value
December 31, 2025 3.281
December 31, 2024 2.251
December 31, 2023 1.906
December 31, 2022 1.054
December 31, 2021 0.0392
December 31, 2020 1.217
December 31, 2019 0.5131
December 31, 2018 0.8504
December 31, 2017 1.185
December 31, 2016 1.38
December 31, 2015 1.113
December 31, 2014 0.49
December 31, 2013 1.015
December 31, 2012 2.483
December 31, 2011 3.645
December 31, 2010 2.789
December 31, 2009 2.580
December 31, 2008 2.108
Date Value
December 31, 2007 1.865
December 31, 2006 1.925
December 31, 2005 1.455
December 31, 2004 1.092
December 31, 2003 0.89
December 31, 2002 0.82
December 31, 2001 0.845
December 31, 2000 0.72
December 31, 1999 0.197
December 31, 1998 0.6206
December 31, 1997 0.6305
December 31, 1996 0.5289
December 31, 1995 0.2809
December 31, 1994 0.3582
December 31, 1993 0.3881
December 31, 1992 0.0983
December 31, 1991 0.4258
December 31, 1990 0.2762

Earnings per Share Definition

Earnings per share measures the total net income / average shares outstanding during income period. There are a few variations to earnings per share that are listed including "EPS Basic", "EPS Diluted", "Normalized Basic EPS", and "Normalized Diluted EPS". Each of these metrics are dependent on which earnings and shares outstanding metrics are used. Basic and Diluted EPS differ in that diluted shares are the amount of shares outstanding after all convertible securities, options, and warrants are exercised. Normalized EPS allows does not include one-time expenses.

Read full definition.

EPS Diluted (Annual) Range, Past 5 Years

View EPS Diluted (Annual) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

EPS Diluted (Annual) Benchmarks

View EPS Diluted (Annual) Benchmarks
Start Trial
GSK Plc 3.660
Johnson & Johnson 11.03
Eli Lilly & Co. 22.95
Merck & Co., Inc. 7.281
Novo Nordisk A/S 3.483